Objectives: Pregnancy is a time of increased HIV acquisition risk and pregnancy reduces concentrations of antiretrovirals used for treatment. We assessed whether pregnancy lowers concentrations of tenofovir (TFV) and tenofovir-diphosphate (TFV-DP) among HIV-uninfected women using oral preexposure prophylaxis (PrEP).
Introduction
Pregnancy is a period of increased risk for HIVacquisition [1] [2] [3] [4] [5] , which may last for a substantial portion of women's reproductive years in settings with a high burden of HIV. Oral tenofovir (TFV)-based PrEP is well tolerated by pregnant women and their infants, and breastfed infants are exposed to very low TFV levels in breastmilk [6] [7] [8] , leading the World Health Organization to provide guidance recommending that PrEP can be safely used during pregnancy and breastfeeding for women at high HIV risk [9] . As PrEP becomes widely used in heterosexual populations, an increasing number of women who are pregnant or trying to become pregnant may use PrEP for HIV prevention [10, 11] .
However, data on the effectiveness of PrEP for HIV prevention during pregnancy are relatively limited. In the clinical trials of PrEP that established its safety and efficacy, women stopped study drug once pregnancy was detected. Pregnancy can affect drug pharmacokinetics in several ways [12] . Most relevant to oral PrEP, pregnancy increases blood volume, leading to a higher volume of distribution, and increases kidney flow rate, leading to higher clearance, with the greatest changes in the third trimester [13, 14] . Increases in volume of distribution can result in lower peak drug concentrations and longer half-lives, whereas increases in clearance can result in lower steady-state drug concentrations and shorter half-lives [15] .
In this analysis, we used stored plasma and dried blood spots (DBS) from an open-label study that included women using PrEP during pregnancy to examine potential differences in blood concentrations of TFV when compared with nonpregnant women, as well as to compare prepregnant and pregnant periods within women. As pregnancy may result in women changing their use of PrEP [16] , we controlled for adherence as measured by electronic monitoring data.
Methods
Women in this analysis were members of mutually disclosed HIV serodiscordant couples who participated in an open-label PrEP demonstration project in Uganda and Kenya (the Partners Demonstration Project), as previously described [17] . Briefly, participants were seen quarterly for up to 24 months. Initially, the study protocol required that women stop using PrEP once pregnant. However, during the study, the protocol was updated at each site and women could continue PrEP (coformulated emtricitabine/TFV disoproxil fumarate 200 mg/300 mg) if they chose to during pregnancy; if they continued PrEP, follow-up became monthly during pregnancy. PrEP adherence was assessed by electronic monitoring [medication event monitoring system (MEMS) caps; WestRock, Switzerland], which recorded daily pill bottle openings; for this analysis, openings were limited to one per day. Blood samples were also taken at quarterly study visits and at monthly visits when pregnant; samples were stored as plasma at À80 8C and, partway through the study, as DBS stored at À20 8C. Age, BMI, and creatinine clearance were assessed at baseline. All participants provided written informed consent in their preferred language.
For this analysis, nonpregnant plasma samples came from a selection of HIV-uninfected women (who never became pregnant or were sampled before their first pregnancy during follow-up): either a random sample tested serially at each study visit or women enrolled in a pharmacokinetic substudy tested at a single study visit. Plasma samples were tested from all pregnant HIVuninfected women who took part in monthly follow-up, as well as any women in the substudy who became pregnant. In addition, we selected one DBS sample from each trimester of pregnancy, as well as a prepregnancy sample when available; one nonpregnant sample was also chosen from a random sample of women. Throughout, samples from women who had less than one recorded PrEP dose in the month prior were excluded as nonusers. When multiple samples were available for the same time period (nonpregnant or trimester), we selected the one with the most recorded doses.
Plasma was tested for TFV and DBS were tested for TFVdiphosphate (TFV-DP), the active metabolite, using ultra-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) [17, 18] . Values below the lower limit of 0.31 ng/ml for plasma TFVand 31.25 fmol/ punch for TFV-DP were set to half the lower limit (0.15 ng/ml and 15.6 fmol/punch, respectively). With a half-life of 14 h in plasma, TFV is a marker of recent use [19] , whereas TFV-DP has a half-life of 17 days in red blood cells and DBS, and provides a marker of cumulative adherence over the prior month [20] .
We compared the mean concentrations of each analyte between pregnant and nonpregnant women using linear models with concentration as the outcome and pregnancy status as the primary predictor; women were not included as both pregnant and nonpregnant in these models (only pregnant samples were included if both were available). As pregnant women could contribute multiple samples while pregnant, generalized estimating equations with an unstructured correlation matrix were used to account for repeated observations. The analysis was then repeated comparing each trimester to nonpregnant women. We next compared the mean concentration of each analyte from prepregnancy to pregnancy among the subset of women who had samples from both time periods; this comparison of pregnancy within woman is conditional on a random intercept for each woman and mixed effects models were used. We conducted two sensitivity analyses: restricting to those samples with TFV above the lower limit of quantitation and restricting to samples with 100% adherence over the prior month, according to MEMS. For all analyses (except the 100% adherence sensitivity analysis), models were adjusted for adherence [number of days with a MEMS opening over the prior month (for TFV-DP), or prior 2 days (for TFV)]. Baseline age, BMI, creatinine clearance, and time in study were tested and only included if they changed the estimated pregnancy effect; we did not adjust for BMI during pregnancy, as changes in weight may be part of the causal pathway. All analyses were conducted in SAS 9.4.
Results

Participant characteristics
Overall, 37 women contributed either plasma or DBS concentrations while pregnant and 97 women contributed only nonpregnant samples. All women were 48 years or younger, with a mean age of 29 at baseline. Overall, 97% were married to their study partner and had an average of 2.4 children ( Table 1) .
Plasma tenofovir concentrations
There were 389 plasma samples (163 from pregnant and 226 from nonpregnant visits) from 116 women (33 pregnant and 83 nonpregnant) available for the comparison between pregnant and nonpregnant women. The average TFV concentration among pregnant women was 34.7 ng/ml, with an average of 22.2 recorded PrEP doses over the prior month; the average TFV concentration among nonpregnant women was 86.5 ng/ml, with an average 23.1 recorded PrEP doses ( Table 2) . After adjusting for adherence, average TFV concentrations were significantly lower among pregnant women, À50.4 ng/ml (95% CI À68.3 to À32.5) ( Table 3) ; this finding translates into a mean concentration of TFV in pregnant women 58% lower compared with nonpregnant women. TFV concentrations were also significantly lower in each trimester (P < 0.001) relative to nonpregnant women: À40.0 ng/ml for the first trimester; À49.4 ng/ml for the second trimester; and À59.2 ng/ml for the third trimester.
In a sensitivity analysis of the 322 samples from 103 women with quantifiable TFV, the results were similar and remained statistically significant, with an adjusted difference of À50.8 ng/ml for pregnant compared with nonpregnant women. Restricting to the 105 samples from 44 women with 100% MEMS adherence over the prior month, the results remained consistent: À51.8 ng/ml for pregnancy overall, À53.9 ng/ml for the Tenofovir levels with PrEP in pregnancy Pyra et al. 1893 Table 2 . Preexposure prophylaxis use and analyte concentrations among pregnant vs. non-pregnant women. first trimester, À48.8 ng/ml for the second trimester, and À52.3 ng/ml for the third trimester compared with nonpregnant women (Fig. 1) . pregnant and nonpregnant women, although the point estimate was lower for pregnant periods: À136.6 fmol/ punch (95% CI À318 to 44.8); in addition, there was a significant difference between the second trimester and nonpregnant periods in adjusted analysis (Table 3 ). In the sensitivity analysis restricted to those with quantifiable TFV-DP, the differences between pregnant (À201.9 fmol/punch), second trimester (À278.4 fmol/ punch), and third trimester (À259.6 fmol/punch) samples were all statistically significantly lower than nonpregnant samples. There were only 30 samples with 100% adherence over the prior month; differences were larger compared with those with quantifiable TFV-DP, but only remained significant in the third trimester (Table 3 and Fig. 1 ).
Prepregnancy and during pregnancy comparisons When comparing levels of TFV among the nine women with plasma samples before and during pregnancy (Table  4) , there was a statistically significant decrease during pregnancy of À28.1 ng/ml after controlling for adherence (Supplemental Table 1 , http://links.lww.com/QAD/ B307); by trimester, only the third trimester was statistically different from prepregnancy. Among 12 women with DBS samples prior to and during pregnancy (Table 4) , there was also a statistically significant decrease during pregnancy, by À289.2 fmol/punch overall and with significant differences in each trimester as well (Supplemental Table 1 , http://links.lww.com/QAD/ B307). These results indicated that concentrations of TFV were 45% lower and concentrations of TFV-DP were 49% lower during pregnancy compared with prepregnancy, controlling for adherence. In both analyses, results were similar when restricted to women with any quantifiable TFV; samples sizes were too small to conduct a sensitivity analysis restricted to 100% adherence over the prior month.
Discussion
Among HIV-uninfected women using oral PrEP, we found that plasma TFV and intracellular TFV-DP in DBS were 45-58% lower during pregnancy compared with nonpregnant periods after adjusting for adherence as measured by MEMS openings. Differences in concentrations were generally larger in the second and third trimester than in early pregnancy. These results suggest that pregnancy alters the pharmacokinetics of oral PrEP among HIV-uninfected women.
Prior studies of TFV used as antiretroviral treatment in pregnant women living with HIV have shown similar results to those we found for HIV-uninfected women using PrEP, though most have focused on United States and European populations. In particular, three studies reported higher TFV clearance during pregnancy (compared with either nonpregnant or postpartum periods) [21] [22] [23] . In addition, two of the studies found lower TFV concentrations in the third trimester compared with postpartum (23% lower C 24 and 20% lower AUC) [22, 23] . In addition, two studies of TFVbased regimens in HIV-infected pregnant women included viral suppression endpoints and found 83 and 94% of women on TFV were virally suppressed in the third trimester, compared with 82 and 85%, respectively, Tenofovir levels with PrEP in pregnancy Pyra et al. 1895 Table 4 . Preexposure prophylaxis use and analyte concentrations before and during pregnancy. in the postpartum period [22, 23] . One study had a target AUC based on the 10th percentile of nonpregnant levels and found that 73% of third trimester samples met the cut-off [22] ; the other study reported no cases of vertical transmission among the 34 women studied, indicating sufficient suppression [23] . Some studies have used higher doses (600 mg TDF/400 mg FTC) at delivery for prevention of mother-to-child transmission and found it was possible to achieve drug exposures similar to nonpregnant populations [24] [25] [26] [27] . Altogether, these findings of similar viral suppression rates in spite of modestly lower TFV levels during pregnancy has led to recommendations in the United States that TDF/FTC dosing in HIV-infected women does not need to be altered during pregnancy [28] .
For PrEP, the clinical significance of the differences in blood concentrations of TFV that we observed is not clear. Clinical trials of PrEP efficacy stopped women from taking PrEP once pregnancy was detected and the number of pregnant users in reported implementation trials to date is too small to conduct efficacy analyses. There is no established protective concentration of TFV for women and protective levels needed for PrEP may differ from suppressive levels when used as ART [19] . Furthermore, it is unclear how blood concentrations of TFV correlate with tissue concentrations at the site of infection or in regional lymph nodes, where the protective action presumably occurs [29] . Prior studies, including a directly observed dosing study, have used 35 ng/ml (or sometimes 40 ng/ml) of serum or plasma TFVas the lower cut-off to indicate consistent, daily PrEP use [29, 30] . In our sample, most participants with 100% adherence by MEMS were above this cut-off, regardless of trimester, although the proportion falling below this threshold increases in pregnancy (Fig. 1) ; the appropriate threshold for TFV-DP is not yet clear.
Pharmacokinetic modeling (in men and women) has suggested that 230 fmol/punch of TFV-DP is equivalent to one dose of PrEP per week [31] and our results suggested that pregnancy has an effect on TFV-DP concentrations of a similar magnitude; in other words, a pregnant woman taking seven doses of PrEP per week would have TFV-DP concentrations similar to a nonpregnant woman taking six doses per week. These results, as well as other work indicating women may need at least six doses per week to achieve protection [32] , suggest that adherence could be even more crucial for women during pregnancy.
Our study has some limitations. This was not a pharmacokinetic study and the exact timing of doses is unknown, making direct comparisons with previous ART studies difficult. MEMS data can be subject to both over and underreporting and there may be residual adherence effects that were not controlled for. However, MEMS data have been shown to correlate well with plasma TFV in prior work in this population [17, 33] . The concentrations among women are lower than expected from direct observation studies. For instance, the mean TFV-DP in nonpregnant women was 636.7 fmol/punch for 20.7 doses/month, or approximately 67% adherence to daily dosing. This value was lower than the mean steady-state TFV-DP observed for 67% adherence in a directly observed dosing study conducted in the United States, 997 fmol/punch [20] , suggesting controlled studies are needed to define TFV-DP in African participants.
Strengths of this study include comparing the effect of pregnancy on plasma TFV and intracellular levels of TFV DP in DBS between pregnant and nonpregnant women, as well as within the same woman over the course of her pregnancy. We accounted for changes in PrEP adherence during pregnancy not only by adjusting for adherence, using electronic monitoring, but also with sensitivity analyses of those with complete adherence over the prior month and of those with biomarker evidence of PrEP use.
In conclusion, concentrations of TFV and its active metabolite TFV-DP appear to be lower during pregnancy in the setting of PrEP; however, most women with high adherence still achieved 35 ng/ml of plasma TFV during pregnancy, which correlated with daily dosing in prior observational studies in this population. Epidemiologic studies within ongoing PrEP implementation projects are needed to determine if the effectiveness of PrEP is altered in pregnancy. Additional pharmacokinetic studies [34] are also warranted to understand the protective threshold of TFV among women. This work also highlights the importance of including pregnant women in research related to the development of novel prevention products [35] .
